Heart Failure Medication Cost Comparison 2026: Entresto vs. Generic Alternatives

Guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF), per the 2022 ACC/AHA/HFSA guidelines updated through 2026, rests on four drug classes prescribed together whenever tolerated: an ARNI (or ACE inhibitor/ARB if the ARNI is not covered or tolerated), a beta blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor. Entresto (sacubitril/valsartan) is the only brand-exclusive, expensive component of this regimen in 2026. The other three foundational classes, ACE inhibitors and ARBs such as lisinopril and losartan, beta blockers such as carvedilol and metoprolol succinate, and the MRA spironolactone, have been available as generics for 15 to more than 30 years and cost a fraction of Entresto's price. This page compares what each pillar costs across major pharmacy chains, Medicare Part D, and Medicaid in 2026.

The Inflation Reduction Act of 2022 changed Entresto's economics for Medicare beneficiaries starting January 1, 2026. CMS negotiated a Maximum Fair Price of $295 per month for brand-name Entresto, a 53% reduction from the roughly $628 pre-negotiation list price. Every Medicare Part D plan, including Medicare Advantage drug plans, must apply this price at the pharmacy counter. Patients managing heart failure alongside diabetes or chronic kidney disease should also check the Jardiance cost guide and the Farxiga cost guide, since SGLT2 inhibitors from either brand are frequently added as a heart failure pillar and both received their own IRA Maximum Fair Prices effective the same date.

Generic competition closed much of the price gap in mid-2025. The FDA approved the first generic sacubitril/valsartan tablets in May 2024, and commercial availability began in July 2025 after patent litigation and settlements were resolved. Manufacturers including Lupin, Novadoz, Camber, Ascend, and Macleods now supply all three tablet strengths at $45 to $80 per month with a discount card. Patients weighing brand Entresto against generic sacubitril/valsartan, or against reverting to an ACE inhibitor or ARB such as atorvastatin's cardiovascular companion drugs, should discuss the clinical tradeoffs with a cardiologist, since ARNI therapy showed a mortality benefit over ACE inhibitors alone in the PARADIGM-HF trial and should not be stopped for cost reasons alone without medical guidance.

What Heart Failure Medications Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same heart failure medications can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Heart failure hospitalizations generate itemized charges for every pillar drug administered during the stay, and Entresto drives most of the markup. Hospitals bill oral medications, including all four heart failure drug classes, as facility line items with markups that commonly run 3x to 8x the pharmacy acquisition cost. A 30-day supply of the three companion generics, worth $10 to $20 combined at acquisition cost, can appear on an itemized inpatient bill at $50 to $200 when spread across a multi-day admission, while Entresto's facility charge alone can reach $500 to $1,100.

Novartis and generic manufacturers negotiate separate acquisition contracts with hospital pharmacies, so the brand-versus-generic price gap seen at retail persists inside the hospital too. Patients discharged with a prescription for brand Entresto rather than generic sacubitril/valsartan should ask the discharge pharmacist whether the generic is clinically appropriate, since switching at discharge, before the first outpatient fill, avoids months of unnecessary brand-price billing. Anyone reviewing a confusing hospital bill that lists heart failure medications at unclear rates can run it through a medical bill analyzer to flag potential overcharges.

Outpatient billing after discharge shifts entirely to Medicare Part D, Medicaid, or commercial insurance rather than the hospital's facility rate. Medicare Part D enrollees pay up to the $295 IRA Maximum Fair Price for brand Entresto, or a lower formulary-tier copay for generic sacubitril/valsartan and the three companion generics, most of which sit on Tier 1 with copays of $0 to $5. Patients with limited income who have not yet checked their eligibility should review the federal poverty level guidelines to see whether they qualify for Extra Help or their state's Medicaid program.

Patient Assistance Programs

Novartis runs two Entresto-specific programs, and both differ sharply from what patients pay for the three companion generic pillars. Commercially insured patients can use the Entresto copay card to cap their cost at $10 per month. Uninsured or underinsured patients who fall at or below 400% of the federal poverty level can receive Entresto free through the Novartis Patient Assistance Foundation (NPAF); that same income-eligible household would pay only $12 to $15 per month total for the three companion generics at Walmart, making the ARNI component the only real financial barrier in the regimen:

Medicare Part D

Medicare Part D, not Part B, covers every drug discussed on this page, since all four heart failure pillars are oral tablets taken at home with no HCPCS J-code or Part B ASP rate. Brand Entresto carries the IRA-negotiated Maximum Fair Price of $295 per month effective January 1, 2026, which all Part D plans must apply at the pharmacy counter. Generic sacubitril/valsartan and the three companion generics are typically placed on a plan's lowest formulary tier, with copays of $0 to $12.65 depending on whether a patient qualifies for Extra Help (the Part D Low Income Subsidy).

Full Extra Help enrollees pay a 2026 copay of $5.10 for generic drugs and $12.65 for brand drugs on a preferred tier, meaning a patient on the all-generic three-pillar regimen plus generic sacubitril/valsartan could pay roughly $20 per month total, versus $295 for brand Entresto alone without Extra Help. Part D enrollees who have not reached the 2026 annual out-of-pocket cap of $2,100 pay their plan's standard cost-sharing up to the $295 MFP ceiling; after the cap is reached, Medicare covers 100% of remaining drug costs for the calendar year. Patients who have not yet applied for Extra Help should check their eligibility before their next Part D renewal.

Common Heart Failure Medications Billing Errors

Because heart failure treatment involves 3 to 5 separate drugs billed simultaneously, billing errors multiply compared to a single-drug prescription. Watch for these specific issues on hospital and pharmacy bills:

• Charged for brand-name Entresto when the pharmacy or hospital actually dispensed generic sacubitril/valsartan (different NDC number, same drug name on the bill)
• Prior authorization denial for brand Entresto that fails to acknowledge the patient already tried and failed an ACE inhibitor or ARB, the standard step-therapy requirement
• Duplicate billing across the inpatient facility claim and the first outpatient pharmacy fill for the same 3-5 day window after discharge
• Plan fails to apply the $295 IRA Maximum Fair Price at the pharmacy counter for Medicare Part D enrollees, instead charging a higher formulary-tier rate for brand Entresto
• Novartis copay card applied to a Medicare or Medicaid claim, prohibited under the federal anti-kickback statute and grounds for claim rejection or fraud referral

Frequently Asked Questions